Skip to main content
. 2019 Jul 18;11(4):390–396. doi: 10.3892/mco.2019.1899

Table IV.

Best response to treatment.

Response to treatment TFTH + BV, n=17 (%)
Complete response (CR) 0 (0)
Partial response (PR) 0 (0)
Stable disease (SD) 12 (71)
Progressive disease (PD) 5 (29)
Not evaluable (NE) 0 (0)
Overall response (CR + PR) 0 (0)
Disease control (CR + PR + SD) 12 (71)

TFTD, trifluridine and tipiracil hydrochloride; BV, bevacizumab.